Pharmaceuticals, Biotechnology and Life Sciences
– Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics – – Completed $60.3 million…
BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of…
Announces signing of $37.8m Supply Assurance Agreement with Merck Organizational changes streamline company and reduce operational expenses Cash runway extended…
Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026 $80 million private placement strengthens…
Updates Full Year 2025 Financial GuidanceRADNOR, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader…
– CHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer – – Q3 2025 ending cash,…
Third-Quarter Net Revenue of $4.8 million; Robust Growth Drives 35% Increase in Net Revenue and Fourth Consecutive Quarter of Profitability…
– CX-2051 Phase 1 data update on track for Q1 2026 – – CX-2051 Phase 1b CRC combination study with…
MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) — BillionToOne, Inc. (Nasdaq: BLLN), a molecular diagnostics company with a mission…
SUNNYVALE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) — BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the…